Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Belzutifan Monotherapy in PPGL, pNET, VHL-Associated Tumors, wt GIST, and HIF-2α–Altered Solid Tumors
2023-504853-11-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), islet cell tumor and 3 more, sponsored by Merck & Co. Primary endpoint: Objective Response. Planned start Jul 2023; status: authorised.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)islet cell tumorvon Hippel–Lindau disease (VHL)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2023-504853-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504853-11-00.